Display Settings:

Format

Send to:

Choose Destination
Am J Clin Pathol. 2012 Jul;138(1):31-41. doi: 10.1309/AJCPXBA69LNSCVMH.

Comprehensive genomic studies: emerging regulatory, strategic, and quality assurance challenges for biorepositories.

Author information

  • 1Laboratory for Translational Pathology, Dept of Pathology and Immunology, Washington University School of Medicine, 660 Euclid Ave, Box 8118, St Louis, MO 63110, USA.

Abstract

As part of the molecular revolution sweeping medicine, comprehensive genomic studies are adding powerful dimensions to medical research. However, their power exposes new regulatory, strategic, and quality assurance challenges for biorepositories. A key issue is that unlike other research techniques commonly applied to banked specimens, nucleic acid sequencing, if sufficiently extensive, yields data that could identify a patient. This evolving paradigm renders the concepts of anonymized and anonymous specimens increasingly outdated. The challenges for biorepositories in this new era include refined consent processes and wording, selection and use of legacy specimens, quality assurance procedures, institutional documentation, data sharing, and interaction with institutional review boards. Given current trends, biorepositories should consider these issues now, even if they are not currently experiencing sample requests for genomic analysis. We summarize our current experiences and best practices at Washington University Medical School, St Louis, MO, our perceptions of emerging trends, and recommendations.

PMID:
22706855
[PubMed - indexed for MEDLINE]
PMCID:
PMC3509484
Free PMC Article

Images from this publication.See all images (3)Free text

Figure 1
Figure 2
Figure 3
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk